Literature DB >> 22341307

Aberrant amplification of the crosstalk between canonical Wnt signaling and N-glycosylation gene DPAGT1 promotes oral cancer.

Basem Jamal1, Pritam K Sengupta, Zhen-Nan Gao, Mihai Nita-Lazar, Bakr Amin, Sharuch Jalisi, Meghan P Bouchie, Maria A Kukuruzinska.   

Abstract

Oral cancer is one of the most aggressive epithelial malignancies, whose incidence is on the rise. Previous studies have shown that in a subset of human oral squamous cell carcinoma (OSCC) tumor specimens, overexpression of the DPAGT1 gene, encoding the dolichol-P-dependent N-acetylglucoseamine-1-phosphate transferase, a key regulator of the metabolic pathway of protein N-glycosylation, drives tumor cell discohesion by inhibiting E-cadherin adhesive function. Recently, we reported that DPAGT1 was a target of the canonical Wnt signaling pathway. Here, we link overexpression of DPAGT1 in human OSCC tumor specimens to aberrant activation of canonical Wnt signaling. We report dramatic increases in β- and γ-catenins at the DPAGT1 promoter and correlate them with reduced expression of a Wnt inhibitor, Dickkopf-1 (Dkk-1). Using human squamous carcinoma cell lines of the head and neck, we show that partial inhibition of DPAGT1 reduces canonical Wnt signaling, indicating that DPAGT1 and canonical Wnt signaling function in a positive feedback loop. We provide evidence that E-cadherin inhibits DPAGT1, canonical Wnt signaling and the OSCC cancer phenotype by depleting nuclear β- and γ-catenins, with hypoglycosylated E-cadherin being the most effective. This suggests that in human OSCC, extensive N-glycosylation of E-cadherin compromises its ability to inhibit canonical Wnt signaling and DPAGT1 expression. Our studies reveal a novel interplay between DPAGT1/N-glycosylation and canonical Wnt signaling and suggest that dysregulation of this crosstalk is a key mechanism underlying OSCC. They also suggest that partial inhibition of DPAGT1 may represent an effective way to restore normal interactions among these essential pathways in oral cancer. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341307      PMCID: PMC3362683          DOI: 10.1016/j.oraloncology.2012.01.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  27 in total

1.  N-glycosylation status of E-cadherin controls cytoskeletal dynamics through the organization of distinct β-catenin- and γ-catenin-containing AJs.

Authors:  Basem T Jamal; Mihai Nita-Lazar; Zhennan Gao; Bakr Amin; Janice Walker; Maria A Kukuruzinska
Journal:  Cell Health Cytoskelet       Date:  2009-09-16

Review 2.  Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors.

Authors:  Michael D Gordon; Roel Nusse
Journal:  J Biol Chem       Date:  2006-06-22       Impact factor: 5.157

3.  Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor.

Authors:  Zahid Khan; Sapna Vijayakumar; Teresa Villanueva de la Torre; Sabrina Rotolo; Anna Bafico
Journal:  Mol Cell Biol       Date:  2007-08-13       Impact factor: 4.272

Review 4.  Towards an integrated view of Wnt signaling in development.

Authors:  Renée van Amerongen; Roel Nusse
Journal:  Development       Date:  2009-10       Impact factor: 6.868

Review 5.  Molecular biology of squamous cell carcinoma of the head and neck.

Authors:  B Perez-Ordoñez; M Beauchemin; R C K Jordan
Journal:  J Clin Pathol       Date:  2006-05       Impact factor: 3.411

6.  Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.

Authors:  Jian-Hong Zuo; Wei Zhu; Mao-Yu Li; Xin-Hui Li; Hong Yi; Gu-Qing Zeng; Xun-Xun Wan; Qiu-Yan He; Jian-Huang Li; Jia-Quan Qu; Yu Chen; Zhi-Qiang Xiao
Journal:  J Cell Biochem       Date:  2011-09       Impact factor: 4.429

7.  E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.

Authors:  Xiaolan Qian; Tatiana Karpova; Allan M Sheppard; James McNally; Douglas R Lowy
Journal:  EMBO J       Date:  2004-04-01       Impact factor: 11.598

8.  Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of Glycosylation Type Ij.

Authors:  Xiaohua Wu; Jeffrey S Rush; Denise Karaoglu; Donna Krasnewich; Mark S Lubinsky; Charles J Waechter; Reid Gilmore; Hudson H Freeze
Journal:  Hum Mutat       Date:  2003-08       Impact factor: 4.878

9.  Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.

Authors:  O Aguilera; M F Fraga; E Ballestar; M F Paz; M Herranz; J Espada; J M García; A Muñoz; M Esteller; J M González-Sancho
Journal:  Oncogene       Date:  2006-02-20       Impact factor: 9.867

10.  E-cadherin mediates adhesion and suppresses cell motility via distinct mechanisms.

Authors:  H Chen; N E Paradies; M Fedor-Chaiken; R Brackenbury
Journal:  J Cell Sci       Date:  1997-02       Impact factor: 5.285

View more
  19 in total

1.  Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response.

Authors:  Jung-Tsu Chen; Chein-Hung Chen; Ko-Li Ku; Michael Hsiao; Chun-Pin Chiang; Tsui-Ling Hsu; Min-Huey Chen; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

2.  DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.

Authors:  Katsuhiko Mitachi; Rita G Kansal; Kirk E Hevener; Cody D Gillman; Syed M Hussain; Hyun Gi Yun; Gustavo A Miranda-Carboni; Evan S Glazer; William M Clemons; Michio Kurosu
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

3.  Inhibition of N-Glycosylation towards Novel Anti-Cancer Chemotherapeutics.

Authors:  Michio Kurosu
Journal:  J Mol Pharm Org Process Res       Date:  2018-01-12

4.  Post-translational glycoprotein modifications regulate colon cancer stem cells and colon adenoma progression in Apc(min/+) mice through altered Wnt receptor signaling.

Authors:  Huabei Guo; Tamas Nagy; Michael Pierce
Journal:  J Biol Chem       Date:  2014-10-01       Impact factor: 5.157

5.  A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.

Authors:  Samantha E Hiemer; Liye Zhang; Vinay K Kartha; Trevor S Packer; Munirah Almershed; Vikki Noonan; Maria Kukuruzinska; Manish V Bais; Stefano Monti; Xaralabos Varelas
Journal:  Mol Cancer Res       Date:  2015-03-20       Impact factor: 5.852

6.  Identification of α1,2-fucosylated signaling and adhesion molecules in head and neck squamous cell carcinoma.

Authors:  Brittany Montesino; Agata Steenackers; Juan M Lozano; Geoffrey D Young; Nan Hu; Robert Sackstein; Kevin Brown Chandler
Journal:  Glycobiology       Date:  2022-04-21       Impact factor: 4.313

7.  N-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration.

Authors:  Gangli Liu; Pritam K Sengupta; Basem Jamal; Hsiao-Ying Yang; Meghan P Bouchie; Volkhard Lindner; Xaralabos Varelas; Maria A Kukuruzinska
Journal:  J Biol Chem       Date:  2013-05-23       Impact factor: 5.157

8.  β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma.

Authors:  Kevin Brown Chandler; Khalid A Alamoud; Vanessa L Stahl; Bach-Cuc Nguyen; Vinay K Kartha; Manish V Bais; Kenichi Nomoto; Takashi Owa; Stefano Monti; Maria A Kukuruzinska; Catherine E Costello
Journal:  Mol Omics       Date:  2020-03-23

9.  Coordinate regulation of N-glycosylation gene DPAGT1, canonical Wnt signaling and E-cadherin adhesion.

Authors:  Pritam K Sengupta; Meghan P Bouchie; Mihai Nita-Lazar; Hsiao-Ying Yang; Maria A Kukuruzinska
Journal:  J Cell Sci       Date:  2012-11-23       Impact factor: 5.285

10.  Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients.

Authors:  Xiao Huo; Xiaoshuang Zhou; Peng Peng; Mei Yu; Ying Zhang; Jiaxin Yang; Dongyan Cao; Hengzi Sun; Keng Shen
Journal:  Onco Targets Ther       Date:  2021-02-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.